Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects (Q87438539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

1 reference

7

Joo-Youn Cho

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Dongseong Shin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Young Min Cho

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

SeungHwan Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Kyoung Soo Lim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jeong-Ae Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ji-Yung Ahn

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Howard Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

In-Jin Jang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Kyung-Sang Yu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

383-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

Metformin + saxagliptin for type 2 diabetes

10 March 2020

cites work

1 reference

12 December 2020

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

12 December 2020

K-cells and glucose-dependent insulinotropic polypeptide in health and disease

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

12 December 2020

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

1 reference

12 December 2020

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

1 reference

12 December 2020

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

1 reference

12 December 2020

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.

1 reference

12 December 2020

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes

1 reference

12 December 2020

Biology of incretins: GLP-1 and GIP

1 reference

12 December 2020

Cellular and molecular mechanisms of metformin: an overview

1 reference

12 December 2020

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.

1 reference

12 December 2020

Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study

1 reference

12 December 2020

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

12 December 2020

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

1 reference

12 December 2020

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

1 reference

12 December 2020

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study

1 reference

12 December 2020

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

12 December 2020

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

1 reference

12 December 2020

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

1 reference

12 December 2020

Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.

1 reference

12 December 2020

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin

1 reference

12 December 2020

Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum

1 reference

12 December 2020

Targeting the glucagon receptor family for diabetes and obesity therapy

1 reference

12 December 2020

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

12 December 2020

10.1007/S40261-014-0184-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24627290%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference